Anthracyclines (such as doxorubicin or daunorubicin) are among the most effective anticancer drugs, but their usefulness is hampered by the risk of irreversible cardiotoxicity. Dexrazoxane (ICRF-187) is the only clinically approved cardioprotective agent against anthracycline cardiotoxicity. Its activity has traditionally been attributed to the iron-chelating effects of its metabolite with subsequent protection from oxidative stress. However, dexrazoxane is also a catalytic inhibitor of topoisomerase II (TOP2). Therefore, we examined whether dexrazoxane and two other TOP2 catalytic inhibitors, namely sobuzoxane (MST-16) and merbarone, protect cardiomyocytes from anthracycline toxicity and assessed their effects on anthracycline antineoplastic efficacy. Dexrazoxane and two other TOP2 inhibitors protected isolated neonatal rat cardiomyocytes against toxicity induced by both doxorubicin and daunorubicin. However, none of the TOP2 inhibitors significantly protected cardiomyocytes in a model of hydrogen peroxide-induced oxidative injury. In contrast, the catalytic inhibitors did not compromise the antiproliferative effects of the anthracyclines in the HL-60 leukemic cell line; instead, synergistic interactions were mostly observed. Additionally, anthracycline-induced caspase activation was differentially modulated by the TOP2 inhibitors in cardiac and cancer cells. Whereas dexrazoxane was upon hydrolysis able to significantly chelate intracellular labile iron ions, no such effect was noted for either sobuzoxane or merbarone. In conclusion, our data indicate that dexrazoxane may protect cardiomyocytes via its catalytic TOP2 inhibitory activity rather than iron-chelation activity. The differential expression and/or regulation of TOP2 isoforms in cardiac and cancer cells by catalytic inhibitors may be responsible for the selective modulation of anthracycline action observed.

Department of Biochemical Sciences Charles University Prague Faculty of Pharmacy in Hradec Kralove Hradec Kralove Czech Republic

Zobrazit více v PubMed

Gianni L, Herman EH, Lipshultz SE, Minotti G, Sarvazyan N, et al. (2008) Anthracycline cardiotoxicity: from bench to bedside. J Clin Oncol 26: 3777–3784. PubMed PMC

Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56: 185–229. PubMed

Deweese JE, Osheroff N (2009) The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing. Nucleic Acids Res 37: 738–748. PubMed PMC

Simunek T, Sterba M, Popelova O, Adamcova M, Hrdina R, et al. (2009) Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep 61: 154–171. PubMed

Keizer HG, Pinedo HM, Schuurhuis GJ, Joenje H (1990) Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity. Pharmacol Ther 47: 219–231. PubMed

Hasinoff BB, Hellmann K, Herman EH, Ferrans VJ (1998) Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines. Curr Med Chem 5: 1–28. PubMed

Tanabe K, Ikegami Y, Ishida R, Andoh T (1991) Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives. Cancer Res 51: 4903–4908. PubMed

Hasinoff BB, Herman EH (2007) Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug? Cardiovasc Toxicol 7: 140–144. PubMed

Sawyer DB (2013) Anthracyclines and heart failure. N Engl J Med 368: 1154–1156. PubMed

Zhang S, Liu X, Bawa-Khalfe T, Lu LS, Lyu YL, et al. (2012) Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 18: 1639–1642. PubMed

Adamcova M, Simunek T, Kaiserova H, Popelova O, Sterba M, et al. (2007) In vitro and in vivo examination of cardiac troponins as biochemical markers of drug-induced cardiotoxicity. Toxicology 237: 218–228. PubMed

Gallagher R, Collins S, Trujillo J, McCredie K, Ahearn M, et al. (1979) Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia. Blood 54: 713–733. PubMed

Chou TC (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58: 621–681. PubMed

Tietze F (1969) Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal Biochem 27: 502–522. PubMed

Mackova E, Hruskova K, Bendova P, Vavrova A, Jansova H, et al. (2012) Methyl and ethyl ketone analogs of salicylaldehyde isonicotinoyl hydrazone: novel iron chelators with selective antiproliferative action. Chem Biol Interact 197: 69–79. PubMed

Glickstein H, El R Ben, Link G, Breuer W, Konijn AM, et al. (2006) Action of chelators in iron-loaded cardiac cells: Accessibility to intracellular labile iron and functional consequences. Blood 108: 3195–3203. PubMed

Kimes BW, Brandt BL (1976) Properties of a clonal muscle cell line from rat heart. Exp Cell Res 98: 367–381. PubMed

Hasinoff BB, Schroeder PE, Patel D (2003) The metabolites of the cardioprotective drug dexrazoxane do not protect myocytes from doxorubicin-induced cytotoxicity. Mol Pharmacol 64: 670–678. PubMed

Swain SM, Vici P (2004) The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review. J Cancer Res Clin Oncol 130: 1–7. PubMed

Espósito BP, Epsztejn S, Breuer W, Cabantchik ZI (2002) A review of fluorescence methods for assessing labile iron in cells and biological fluids. Anal Biochem 304: 1–18. PubMed

Bendova P, Macková E, Hašková P, Vávrová A, Jirkovský E, et al. (2010) Comparison of clinically used and experimental iron chelators for protection against oxidative stress-induced cellular injury. Chem Res Toxicol 23: 1105–1114. PubMed

van Dalen EC, Caron HN, Dickinson HO, Kremer LCM (2011) Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database of Systematic Reviews: 71. PubMed

Štěrba M, Popelová O, Vávrová A, Jirkovský E, Kovaříková P, et al. (2013) Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection. Antioxid Redox Signal 18: 899–929. PubMed PMC

Wouters KA, Kremer LCM, Miller TL, Herman EH, Lipshultz SE (2005) Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br J Haematol 131: 561–578. PubMed

Malisza KL, Hasinoff BB (1995) Doxorubicin reduces the iron(III) complexes of the hydrolysis products of the antioxidant cardioprotective agent dexrazoxane (ICRF-187) and produces hydroxyl radicals. Arch Biochem Biophys 316: 680–688. PubMed

Popelová O, Sterba M, Hasková P, Simůnek T, Hroch M, et al. (2009) Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death. Br J Cancer 101: 792–802. PubMed PMC

Martin E, Thougaard AV, Grauslund M, Jensen PB, Bjorkling F, et al. (2009) Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy. Toxicology 255: 72–79. PubMed

Hasinoff BB, Schnabl KL, Marusak RA, Patel D, Huebner E (2003) Dexrazoxane (ICRF-187) protects cardiac myocytes against doxorubicin by preventing damage to mitochondria. Cardiovasc Toxicol 3: 89–99. PubMed

Schroeder PE, Jensen PB, Sehested M, Hofland KF, Langer SW, et al. (2003) Metabolism of dexrazoxane (ICRF-187) used as a rescue agent in cancer patients treated with high-dose etoposide. Cancer Chemother Pharmacol 52: 167–174. PubMed

Lyu YL, Kerrigan JE, Lin CP, Azarova AM, Tsai YC, et al. (2007) Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res 67: 8839–8846. PubMed

Vávrová A, Popelová O, Stěrba M, Jirkovský E, Hašková P, et al. (2011) In vivo and in vitro assessment of the role of glutathione antioxidant system in anthracycline-induced cardiotoxicity. Arch Toxicol 85: 525–535. PubMed

Hasinoff BB, Yalowich JC, Ling Y, Buss JL (1996) The effect of dexrazoxane (ICRF-187) on doxorubicin- and daunorubicin-mediated growth inhibition of Chinese hamster ovary cells. Anticancer Drugs 7: 558–567. PubMed

Larsen AK, Escargueil AE, Skladanowski A (2003) Catalytic topoisomerase II inhibitors in cancer therapy. Pharmacology & Therapeutics 99: 167 − 181. PubMed

Fujiwara Y (1999) Current status of oral anticancer drugs in Japan. J Clin Oncol 17: 3362–3365. PubMed

Inutsuka S, Baba H, Maehara Y, Sugimachi K (1998) MST-16, a novel derivative of bis(2,6-dioxopiperazine), synergistically enhances the antitumor effects of anthracyclines. Cancer Chemother Pharmacol 42: 194–200. PubMed

Lu DY, Huang M, Xu CH, Yang WY, Hu CX, et al. (2005) Anti-proliferative effects, cell cycle G2/M phase arrest and blocking of chromosome segregation by probimane and MST-16 in human tumor cell lines. BMC Pharmacol 5: 11. PubMed PMC

Minderman H, Linssen P, Wessels J, Haanen C (1993) Cell cycle related uptake, retention and toxicity of idarubicin, daunorubicin and doxorubicin. Anticancer Res 13: 1161–1165. PubMed

Cooney DA, Covey JM, Kang GJ, Dalal M, McMahon JB, et al. (1985) Initial mechanistic studies with merbarone (NSC 336628). Biochem Pharmacol 34: 3395–3398. PubMed

Austin CA, Marsh K (1998) Eukaryotic DNA topoisomerase IIß. Bioessays 20: 215–226. PubMed

Vávrová A, Šimůnek T (2012) DNA topoisomerase IIβ: a player in regulation of gene expression and cell differentiation. Int J Biochem Cell Biol 44: 834–837. PubMed

Low RL, Orton S, Friedman DB (2003) A truncated form of DNA topoisomerase IIbeta associates with the mtDNA genome in mammalian mitochondria. Eur J Biochem 270: 4173–4186. PubMed

UHPLC-MS/MS method for analysis of sobuzoxane, its active form ICRF-154 and metabolite EDTA-diamide and its application to bioactivation study